Recent Comments
  • Loading...
Links
Tags

Archive for the ‘Oncology’ Category

4/4/11 – Expansion Update

Thursday, June 9th, 2011

Read more...

A Career as a Pharmacist

Wednesday, June 8th, 2011

A Career as a Pharmacist Read more...

Microplate Reader Accelerating Cell Science – LIVE at AACR 2010 in Washington, DC.

Saturday, June 4th, 2011

Read more...

Lower Revs Widen Loss at Alnylam

Monday, May 9th, 2011

Lower Revs Widen Loss at Alnylam
Alnylam’s Q1 loss of 38 cents per share was wider than the Zacks Consensus Estimate of 32 cents per share and the year-ago loss of 29 cents per share.
Read more on Zacks.com via Yahoo! Finance

Read more...

MDxHealth Wins $1.1M Grant to Progress Cancer Program

Friday, May 6th, 2011

MDxHealth Wins .1M Grant to Progress Cancer Program
DURHAM, N.C. & LIEGE, Belgium–(BUSINESS WIRE)–MDxHealth SA (NYSE Euronext: MDXH), a leading mo…
Read more on citybizlist Charlotte/Raleigh

Read more...

Unconventional Cancer Treatment Methods

Thursday, May 5th, 2011

Unconventional Cancer Treatment Methods Read more...

Alliance HealthCare Services Reports Results for the First Quarter Ended March 31, 2011 and Reaffirms Full Year 2011 …

Tuesday, May 3rd, 2011

Alliance HealthCare Services Reports Results for the First Quarter Ended March 31, 2011 and Reaffirms Full Year 2011 …
NEWPORT BEACH, Calif.–(BUSINESSWIRE)– Alliance HealthCare Services, Inc. (the “Company” or “Alliance”), a leading national provider of outpatient diagnostic imaging and radiation therapy services, …
Read more on Business Wire Finance Press Releases UK via Yahoo! UK & Ireland Finance

Read more...

How to deal with challenging news when advanced cancer occurs. Drs. Paul Brenner and Dan Vicario

Thursday, April 21st, 2011

Read more...

Symphogen Names New Chief Scientific/Medical and Business Officers

Wednesday, April 20th, 2011

Symphogen Names New Chief Scientific/Medical and Business Officers
COPENHAGEN, Denmark–(BUSINESS WIRE)–Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced today the completion of its senior management team with the addition of a new Chief Scientific/Medical Officer, Ivan D. Horak, M.D., FACP and a new Chief …
Read more on Business Wire

Read more...

Gene Modulation Innovation with Thermo Scientific – LIVE at AACR 2010 in Washington, DC.

Friday, April 1st, 2011

Read more...